Study objective: To investigate the initial and long-term effect of nitric oxide (NO) Recently, it has been described that in severe ARDS, NO inhalation is not always able to reduce mean pulmonary artery pressure (PAP) and to increase the arterial partial pressure of oxygen (PaO2).4 However, no study investigated how often NO fails to reduce pulmonary hypertension or to improve arterial oxygenation. Furthermore, only limited experiences exist in long-term inhalation of NO, and so far, to our knowledge, there is no information available whether NO inhalation has a positive effect on the survival rate in these patients. Controlled prospective multicenter trials, focusing on the question of whether NO inhalation will result in an increase of survival in patients with severe ARDS, will not be available within the near future. Therefore, we retrospectively studied the initial and long-term effects CHEST /
Inhalation of low concentrations of the gaseous va- sodilator nitric oxide (NO) has been described to cause selective pulmonary vasodilation. Recently, it has been described that in severe ARDS, NO inhalation is not always able to reduce mean pulmonary artery pressure (PAP) and to increase the arterial partial pressure of oxygen (PaO2).4 However, no study investigated how often NO fails to reduce pulmonary hypertension or to improve arterial oxygenation. Furthermore, only limited experiences exist in long-term inhalation of NO, and so far, to our knowledge, there is no information available whether NO inhalation has a positive effect on the survival rate in these patients. Controlled prospective multicenter trials, focusing on the question of whether NO inhalation will result in an increase of survival in patients with severe ARDS, will not be available within the near future. Therefore, we retrospectively studied the initial and long-term effects CHEST of inhaled NO on gas exchange, hemodynamics, and methemoglobin formation in patients with severe ARDS in our ICU. In addition, we made an attempt to estimate whether NO inhalation has a profound effect on mortality of our patients with ARDS.
METHODS

Patients
From April 1989 to August 1993, 87 patients with ARDS, aged from 1 to 62 years, without a history of previous lung disease, were referred to our hospital for treatment, including the possible application of veno-venous extracorporeal membrane oxygenation (ECMO). All patients had severe ARDS according to the lung injury scoring system of Murray et a15 (ARDS score range, 2.5 to 4) that assesses the degree of diffuse radiographic infiltration, arterial hypoxemia, respiratory compliance, and the level of positive end-expiratory pressure (PEEP).5 Patients with pulmonary edema due to cardiac failure, immunosuppression, and advanced malignant disease were excluded. Additional organ failures were determined modifying the score described by Goris et al.6
After transfer to our ICU, all patients received standard treatment7 that consisted of pressure-controlled mechanical ventilation with 10 to 15 cm H20 PEEP and a maximum inspiratory peak pressure less than 40 cm H20 using one of two ventilators (either a Servo 900C ventilator, Siemens Elema, Lund, Sweden, or a Siemens 300 Siemens Elema, Lund, Sweden), positioning maneuvers (change of supine and prone position), adequate dehydration, if fluid overload was present, side differential ventilation in patients with unilaterally pronounced infiltrates, and acceptance of partial pressures of carbon dioxide (PaCO2) up to levels of 80 mm Hg, if pH remained above 7.25 and if no head injury was present. When patients had life-threatening hypoxemia (PaO2<50 mm Hg at an inspiratory oxygen fraction (FIo2) of 1.0 and PEEP> 10 cm H20 for >2 h) or did not respond to the therapeutic means listed above, veno-venous ECMO with heparin-coated systems was performed as described elsewhere.8
From April 1991 to August 1993, 30 patients with PaO2/ FIo2<200 mm Hg were additionally treated with NO inhalation using concentrations between 0.01 and 25 parts per million (ppm). Since only one device with a safe administration technique, including NO/nitric dioxide monitoring was available, only one patient could be treated at the same time. In patients receiving NO (NO group), NO inhalation began 7.4 + 1.7 days (range, first and 32nd day) after the patient's admission to our ICU. At that time, the patients had already been mechanically ventilated for an average of 20.1 + 1.6 days.
Of the 30 patients 16 were also treated with veno-venous ECMO because pulmonary venous admixture (QVA/QT) remained over 45% resulting in severe arterial hypoxemia. All inhalation was correlated with baseline pulmonary vascular resistance and Qvk/QT, respectively. Also, the change in PAP due to NO inhalation was correlated with the degree of pulmonary hypertension before NO inhalation, and the decrease in QvA/QT after NO inhalation was correlated with QVA/QT before NO inhalation. The changes in PaO2/FIo2, QVA/QT, and PAP after NO inhalation were correlated with cardiac index before NO inhalation.
Effects of Prolonged Inhalation of NO
The patients continuously inhaled NO for more than 48 h if they were either responders with respect to an improvement in arterial oxygenation or responders with respect to reduction in PAP. To determine the effect of withdrawal and resumption of NO on hemodynamics and gas exchange, the continuous inhalation of NO was stopped daily for 30 min at constant ventilator settings with an FIo2 between 0.9 and 0.98. The NO therapy was terminated reducing the NO concentration step by step over 24 h when the PaO2/FIo2 had risen above 300 mm Hg during the daily tests without NO inhalation. Methemoglobin levels were analyzed before and during NO inhalation.
Analysis of Survival
We analyzed survival rates (defined as discharge from hospital) in the NO group and compared it with the survival rates of the patients not receiving NO. For this purpose, matched pairs of patients who have been treated and who have not been treated with inhaled NO were retrospectively formed if the severity of ARDS was similar. Since children younger than 10 years (n=3) were present only in the NO group, they were excluded from this part of the study. For the formation of matched pairs, the following criteria were chosen. First, patients receiving extracorporeal support were matched only with patients who had also been treated with ECMO. Moreover, they had to be equal concerning fulfilling the fast or the slow entry criteria for ECMO. Second, all other patients were allowed to have maximum differences in the PaO2/FIo2 ratio of 30 mm Hg and maximum differences in the lung injury score5 of 0.5. Third, due to the higher mortality in ARDS caused by pneumonia,'01' patients with this diagnosis as underlying disease were matched only with patients also suffering from ARDS due to pneumonia. Fourth, the number of additional organ failures was not allowed to differ by more than 1.
Statistical Analysis
All data were expressed as mean values ± SE. The initial response to NO inhalation was determined as the difference between the baseline value and the value during intervention. Effects of long-term inhalation are reported as the difference of the mean values recorded during treatment and cessation of NO inhalation. Because normal distribution could not be proved, the Wilcoxon rank sum test was used to compare values recorded during NO inhalation with those recorded without NO inhalation as well as to compare methemoglobin values before NO inhalation with the values during NO inhalation.
When a linear regression was calculated, Pearson's coefficient of correlation (r) was tested using a t distribution.
To find out differences in survival rates and sex, the x2 test was used. To analyze differences between the matched pairs, the Mann-Whitney test was used to compare patients' further characteristics. All tests of significance were two-tailed, and p values less than 0.05 were regarded as significant.
RESULTS
Effects of First Inhalation of NO The first inhalation of NO Cl before NO-iiuhalaliont I1/minlIm-2 Norepinephrine or other cardiotonic agents that might influence the response of vessels to NO inhalation had to be infused to some responders and to some nonresponders.
The increase in PaO2/FIo2 due to NO inhalation did not correlate with the pulmonary vascular resistance index before NO inhalation (r=0.04); furthermore, the decrease in PAP and in QvA/QT following NO inhalation was independent of QvA/QT before NO inhalation (r=0.35 and r=0.39, respectively) ( Figure 1, a and b) . There was no correlation between the effect of NO inhalation on PAP and PAP before NO inhalation (r=0.28) (Fig 1, c) . The change in PaO2/FIo2, QvA/QT, and PAP due to NO inhalation did not correlate with CI before NO inhalation (r=0.22, r=0.30, and r=0.14) (Fig 1, d through f patients demonstrated no difference in survival between the NO group and the non-NO group (69 vs 69%). In addition to three children out of the NO group, one patient of this group suffering from ARDS following pneumonia had to be excluded from this part of the study, as no patient could be found in the non-NO group who fulfilled the matching criteria.
DISCUSSION
The present study investigates the efficacy of NO inhalation in 30 patients with severe ARDS and basically confirms the findings of our earlier study3 that inhaled NO causes vasodilation predominantly in ventilated lung areas and, thereby, improves arterial oxygenation and reduces pulmonary hypertension in patients with severe ARDS. In addition, we demonstrated that in some patients, NO 
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improve pulmonary gas exchange and to reduce pulmonary hypertension. We also can only speculate on the cause for the nonresponsiveness to inhaled NO in our patients. One reason might be that four of these five had QVA/QT of more than 50% (Table 1 ). This could have reduced the selective vasodilatory activity of NO to such a small lung area that global beneficial effects did not result. However, this hypothesis is in contrast to the finding that, in our study, four patients with QVA/QT of more than 50% were among the responders. Recently, Putensen et al'2 described the association of an improvement in the ventilation/ perfusion mismatch due to inhaled NO with the recruitment of lung units with the use of PEEP. These authors administered an inhalation gas mixture containing 40 ppm NO to dogs with acute lung injury using ambient airway pressure or continuous positive airway pressure (CPAP). In both groups, inhaled NO caused selective pulmonary vasodilation. However, NO inhalation decreased only the intrapulmonary shunt and improved pulmonary gas exchange, when simultaneously lung units were recruited with CPAP.
Although in the present study all patients were ventilated using PEEP between 10 and 15 cm H20, it cannot be excluded that the PEEP level may have been insufficient to recruit enough alveoli for a redistribution of blood flow from nonventilated toward ventilated lung units after NO inhalation. However, since PEEP may cause overexpansion of healthy lung areas, the resulting mechanical compression on the pulmonary blood vessels may limit the vasodilatory effect of inhaled NO. Interestingly, four of the five initial PaO2 nonresponders became responders when reevaluating inhaled NO routinely 3 to 5 days later. In these patients, the PEEP level was unchanged; however, it might be that owing to a change in the patients' conditions at the time of reevaluation, this PEEP was more appropriate to recruit or to avoid overdistention of lung units. Furthermore, the lack in response to NO inhalation could be caused by an ineffective concentration of NO. Dose-response studies showed that, in general, the effect of NO on PaO2 was significant at 0.1 ppm, whereas the effect of NO on PAP was significant only with concentrations of 1 ppm and more.14 The idealized dose-response curves for PaO2 and PAP showed different patterns: the improvement in oxygenation with 50% maximal response (ED50) at about 0.1 ppm had a maximum at 10 ppm NO and, at the highest tested concentration (100 ppm), drifted back toward the baseline data, whereas PAP presented a continuous, dose-dependent downwards tendency with an ED50 of approximately 2 to 3 ppm NO.13 This may be based on a diffusion of NO at high concentrations not only to ventilated but also to nonventilated lung areas. Thereby, the intrapulmonary shunt may increase and the arterial oxygenation may deteriorate. Whereas these were general observations, this study by Gerlach et al'3 revealed, in addition, the individually different pattern of response to increasing concentrations of inhaled NO. Since in the present study we used only one concentration for the analysis of the first inhalation of NO (10 to 20 ppm), we cannot exclude that this concentration was individually too high or too low to cause the desired effects on pulmonary gas exchange and hemodynamics. Therefore, for future studies, we propose individual repetitive dose-response analysis to exclude false-negative responses concerning an improvement in arterial oxygenation and a reduction in pulmonary hypertension due to inadequate concentrations of inhaled NO.
Trying to find factors influencing the effect of inhaled NO, we analyzed the correlation between several parameters. However, the increase in PaO2/FIo2 due to NO inhalation did not correlate with the pulmonary vascular resistance index; also, the decrease in PAP following NO inhalation was not dependent on QvA/QT before NO inhalation. In contrast to Bigatello et al,'4 who demonstrated in seven patients with ARDS that the magnitude of the vasodilator response during NO inhalation correlated with the degree of vasoconstriction when stopping NO inhalation, we found no correlation between the effect of NO inhalation on PAP and PAP before NO inhalation. Furthermore, also in contrast to these authors, 15 we could not demonstrate that the decrease in QvA/QT due to NO inhalation correlated with QVA/QT before NO inhalation. Moreover, we were not able to demonstrate that the effect of NO inhalation correlated with CI. In addition, we observed responders and nonresponders independent of the necessity for ECMO or intravenous catecholamine infusions. We conclude that, at present, the efficacy of inhaled NO in patients with such severe ARDS cannot be predicted.
In accordance with our previous study3 and also in this study, continuous inhalation of low concentrations of NO remained effective for 17 ± 2.4 days in improving pulmonary gas exchange and reducing pulmonary hypertension. Also, we could not observe tachyphylaxis or a more pronounced effect of NO inhalation over time, ie, that the effect of inhaled NO on PaO2/FIo2 and PAP determined with the brief daily periods when NO inhalation was discontinued was similar both at the end of treatment and at the beginning. So, adding NO to the inhaled gas facilitated a reduction of FIo2, which minimizes the exposure to high inhaled oxygen concentrations and may reduce pulmonary oxygen toxic reactions. 15 we do not believe that nitric dioxide formation influenced survival in our patients.
Therefore, we believe that the observed identical survival rate in both groups allows three statements. First, if low concentrations of NO as well as appropriate delivery and monitoring systems are used, NO inhalation appears to be safe. Second, NO inhalation has no striking effect on outcome in patients with severe ARDS; hence, at present, the treatment of severe ARDS with NO inhalation cannot be considered mandatory, which might be suggested by the presented data regarding the effect of NO inhalation on arterial oxygenation and pulmonary hypertension. Third, the identical survival rate of both groups implies the need for controlled randomized clinical trials to answer the question of whether NO inhalation will result in an increase of survival in patients with ARDS. However, the difficulty of such outcome studies is that patients with ARDS demonstrate multifactorially determined problems, which make it difficult to identify outcome changes due to a specific intervention.28 Although a one-center trial such as ours may have the advantage that at least the routine therapeutic approach can be standardized easily, a controlled randomized one-center trial is unlikely to demonstrate an improved outcome following a new therapy, if only a limited number of patients can be included and if the new therapy will not dramatically improve survival. Therefore, a controlled randomized multicenter trial is required, even if multicenter studies will have the problem that the routine treatment of patients with ARDS consisting of a variety of therapeutic means will vary in many details among the centers. Consequently, multicenter studies most probably will have to enroll a huge number of patients.
In conclusion, the present study demonstrated that although we observed the beneficial effects of NO on PaO2 and PAP in most patients, NO inhalation may fail to improve pulmonary gas exchange or to reduce pulmonary hypertension in patients with severe ARDS. At present, no parameter or condition in patients with severe ARDS has been shown that may allow us to predict the efficacy of inhaled NO. To demonstrate any increase in survival adding NO inhalation to the standard treatment, large controlled randomized trials are both justified and required.
